Physician profile

William E Hughes

Urology · Decatur, AL

NPI 1053366641

$5,579.93

in general payments reported to CMS, 2019-2025

45 companies · $1,181 in 2025

The $1,181 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,408.42
Education$90.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sumitomo Pharma America, INC. $1,191.91 2023-2025 Gemtesa, Orgovyx
Astellas Pharma US INC $687.82 2019-2024 Myrbetriq
Antares Pharma, INC. $491.85 2019-2025 Xyosted, Tlando
Abbvie INC. $263.96 2022-2025
Procept Biorobotics Corporation $236.30 2023-2025 Aquabeam System, Aquabeam Robotic System
Boston Scientific Corporation $225.13 2019-2025 Rezum Generator, Lithovue
Endo Pharmaceuticals INC. $197.35 2019-2024 Xiaflex
Janssen Biotech, INC. $185.17 2025 Erleada
Clarus Therapeutics INC. $153.45 2021
Medtronic, INC. $140.45 2023-2024 Interstim
Pfizer INC. $134.18 2019-2024
Myovant Sciences INC. $133.19 2021-2022
Axonics, INC. $126.87 2023-2024 Axonics, Bulkamid
Progenics Pharmaceuticals, INC. $121.17 2021-2025 Pylarify
Endo USA, INC. $105.64 2024 Xiaflex
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $86.10 2020-2024
Coloplast Corp $80.84 2019-2025
Myriad Genetic Laboratories, INC. $76.56 2020-2024 Prolaris
Tolmar Pharmaceuticals, INC. $72.64 2019-2021
Laborie Medical Technologies Corp. $66.87 2024-2025 Optilume Bph Drug Coated Balloon Catheter, Urgent PC Neuromodulation System
Halozyme INC $62.15 2023
Kowa Pharmaceuticals America, INC. $59.84 2022-2023 Seglentis
Allergan, INC. $58.96 2021-2022
Ferring Pharmaceuticals INC. $57.00 2024-2025 Adstiladrin
Tolmar, INC. $54.16 2024-2025 Eligard, Jatenzo
Alnylam Pharmaceuticals INC. $46.81 2021
180 Medical, INC. $43.90 2021-2024 Gentlecath Glide
Olympus America INC. $41.38 2019-2025 Itind System
Merck Sharp & Dohme LLC $39.83 2022-2025 Lynparza
Urogen Pharma, INC. $37.49 2021-2023 Jelmyto
Immunitybio, INC. $34.41 2025
Janssen Scientific Affairs, LLC $32.24 2019
Teleflex LLC $31.20 2025 Barrigel
Kerecis Limited $25.14 2025 Kerecis Surgiclose, Kerecis Graftguide
Travere Therapeutics, INC. $21.83 2020-2021
Verity Pharmaceuticals INC. $19.96 2023 Trelstar
Zyla Life Sciences, INC. $17.71 2020
Baxter Healthcare $17.03 2022
Rochester Medical Corporation $16.53 2021
Foundation Medicine, INC. $14.89 2020
Lilly USA, LLC $14.31 2021
Astrazeneca Pharmaceuticals LP $14.05 2022
Novo Nordisk INC $14.02 2024
E.R. Squibb & Sons, L.L.C. $13.93 2022
Photocure INC $13.71 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

William E Hughes

$5,579.93

in general payments reported 2019-2025

Years
2019-2025
Top company
Sumitomo Pharma America, INC.
Context
The $1,181 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/563724/william-e-hughes

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.